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Introduction: Lung cancer is the leading cause of cancer mortality
worldwide. We analyzed changes in treatment and their potential
effect on survival of non-small cell lung cancer (NSCLC) patients in
the Netherlands.
Methods: All NSCLC patients diagnosed during 1989–2009 (n 
147,760) were selected from the population-based Netherlands Can-
cer Registry. Differences in treatment over time were tested by the
Cochran-Armitage trend test. The effects of sex, age, histology, and
treatment on relative survival were estimated in multivariable mod-
els. Follow-up was completed until January 1, 2010.
Results: Between 1989 and 2009, the proportion of younger patients
(younger than 75 years) with stage I undergoing surgery increased
from 84 to 89% and among elderly (75 years or elder) from 35 to
49%; for stage II, this proportion decreased from 80 to 70% and
remained about 25% in respectively younger and older patients.
Adjuvant chemotherapy for stage II increased to from 0 to 24% in
younger patients but remained less than 5% among the elderly.
Chemoradiation increased from 8 to 43% among younger patients
with stage III and from 1 to 13% among elderly. In stage IV,
chemotherapy in younger patients increased from 10 to 54% and in
elderly from 5 to 21%. Five-year relative survival of the total group
increased from 14.8 to 17% (especially among females, younger
patients, and within each stage), which could be partly explained by
changes in treatment and better staging.
Conclusions: Over a 20-year period, application of therapy, which
is currently considered as standard, has improved. This resulted in
small improvements in survival within all stages.
Key Words: Non-small cell lung cancer, Trends, Survival, Treat-
ment, Population-based.
(J Thorac Oncol. 2012;7: 291–298)
Lung cancer is still the leading cause of cancer mortalityworldwide. The incidence of lung cancer in males is
declining in developed countries following the significant
decreased tobacco consumption; in the Netherlands, the age-
standardized incidence rate decreased from 82 to 54 per 100,000
person-years between 1989 and 2009 (www.ikcnet.nl).1,2 Inci-
dence rates in females increased from 11 per 100,000 in 1989
to 29 in 2009 but are flattening out among young women.3
The majority (80–89%) of all lung cancers are non-small cell
lung cancers (NSCLC).2,4 The distribution of histology and
stage has changed in the past 20 years, with an increase in the
proportion of patients with adenocarcinoma and stage IV
disease.5–7 Improved staging techniques such as application
of fluorodeoxyglucose-positron emission tomography and en-
doscopical ultrasound biopsies from mediastinal lymph
nodes, combined with changes in the TNM (tumor, node,
metastasis) classification system in 1997, resulted in stage
migration.8–12
At the time of diagnosis, NSCLC patients often have
systemic disease resulting in an overall 5-year survival rate of
only 16%.4,13 During the past 20 years, refinements in surgery
and perioperative care, radiotherapy, and chemotherapy have
been made enabling the combination of different (new) mo-
dalities.14–16 In clinical trials with selected patients, mostly
with a good performance status and younger age, these new
modalities have shown slight improvements in 1- and 5-year
survival. Standard treatment in the Netherlands is described
in the “national guideline for staging and treatment of
NSCLC” published in 2004 and was recently updated in
2011. The broad categories for treatment are surgery for
stages I and II, chemoradiation for stage III, and chemother-
apy for stage IV (www.ikcnet.nl). The question remains how
changes in patient selection for these treatment categories
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affected survival in daily practice. The period before the
introduction of the 2004 guideline (1989–2004) was used as
start of our measurements.
The aim of this study was to examine changes in
treatment and survival of NSCLC patients in the Netherlands
in the last 20 years, on a population-based level, according to
stage, age group, and sex.
METHODS
Data Collection
Population-based data from the nationwide Netherlands
Cancer Registry was used which has complete national cov-
erage and registers about 90,000 new cancer cases annually.17
Follow-up was calculated as the time from diagnosis to death
or to January 1, 2010. The information on vital status was
initially obtained from municipal registries and hospitals and
from 1995 onward from the nationwide population registries
network. These registries provide virtually complete cover-
age of all deceased Dutch citizens.
For this study, all patients diagnosed with microscopi-
cally verified NSCLC (C34, ICD-O morphology codes 8010-
14, 8020-22, 8030-33, 8046, 8050-78, 8082-84, 8090, 8094,
8123, 8140-41, 8190, 8200, 8211, 8230-31, 8250-63, 8290,
8310, 8323, 8333, 8430, 8470-90, 8550-51, 8560, 8562,
8570-75, 8972, 8980-82) during the period 1989–2009 in the
Netherlands were included. Histology was classified as squa-
mous cell carcinoma, adenocarcinoma, and large cell carci-
noma according to the World Health Organization classifica-
tion.18 A subgroup of other histologies consisted of
adenosquamous and sarcomatoid tumors, among others. The
study period was divided into four categories: 1989–1993,
1994–1998, 1999–2003, and 2004–2009. Age was divided
into three groups (60, 60–74, and 75 years). The 6th
edition of TNM classification was used for staging of lung
tumors.19 The clinical TNM (cTNM) was used in trend
analysis of primary treatment according to stage. For the
cases where cTNM was unknown (11%), the pathological
stage (pTNM) was added if known (5%). Primary treatment
was classified as surgery (with or without chemotherapy and/or
radiotherapy), thoracic radiotherapy, chemotherapy and thoracic
radiotherapy (chemoradiation), chemotherapy alone, and best
supportive care. For survival analysis, pTNM was applied, and
if pTNM was unknown, cTNM was used.
Statistical Analysis
The percentage of patients receiving certain types of
treatment was calculated by age group and time period.
Differences in treatment over time were tested by the Coch-
ran-Armitage trend test. Relative survival was used as an
estimation of disease-specific survival and is calculated as the
ratio of the observed rates in cancer patients to the expected
rates in the general population.20 It reflects survival of cancer
patients, adjusted for survival in the general population with
the same age and gender distribution. Patients younger than
15 years and older than 95 years were excluded from survival
analyses, as well as cases diagnosed by autopsy. Traditional
cohort-based relative survival analysis was used for the pe-
riod 1989–2003. As follow-up was available until January
2010, 5 years of follow-up was not available for the period
2004–2009, and therefore period-based relative survival
analysis was conducted to obtain 5-year relative survival in
this recent period.21 For stages I and II, 5-year relative
survival was calculated, for stage III 3-year, and stage IV
1-year relative survival. Survival trends were evaluated by a
linear regression model and p  0.05 was considered as
statistically significant.
Multivariable relative survival analyses were per-
formed to estimate relative excess risk (RER) of mortality for
the periods of diagnosis adjusted for follow-up time, age, sex,
and histology and stratified by stage. Treatment variables
were added to investigate whether the effect of time period on
survival could be explained by changes in treatment. The
difference in RER is the part that was explained by changes
in treatment. SAS software (SAS system 9.2, SAS Institute,
Cary, NC) was used to perform the statistical analyses.
RESULTS
Patient Characteristics
Patient characteristics are presented in Table 1. During
the period 1989 to 2009, 147,760 patients were diagnosed
with NSCLC. The proportion of females more than doubled
from 15% in 1989–1993 to 34% in 2004–2009. The median
age has slightly increased among males from 69 years in
1989–1993 to 70 years in 2004–2009 (p  0.001) but
remained stable at 64 years among females. Twenty-five
percent of the patients was 75 years or older at the time of
diagnosis.
The proportion of patients with unknown stage de-
creased from 9% in 1989–1993 to 2% in 2004–2009. After
1999, the proportion of patients with advanced disease (stage
IV) increased from about 27 to 44% in 2004–2009, whereas
the proportions of patients with stage I (about 27 to 20%) and
III (about 37 to 30%) decreased. Over time, the proportion of
nonsquamous cell carcinomas among male patients increased
from 42 to 67%, independent of age, and among females from
67 to 81% with a stronger increase for those younger than 60
years (results not shown).
Trends in Treatment
Stages I and II
Since 1989, the percentage of patients with stage I
disease undergoing resection remained about 91% among
those younger than 60 years and increased from 77 to 82%
among those aged 60 to 74 years (p  0.001) and from 35 to
49% among patients aged 75 years or older (p  0.001).
Since 2003, the proportion of patients younger than 75 years
receiving (neo-)adjuvant chemotherapy increased signifi-
cantly, whereas (neo-)adjuvant radiotherapy decreased (Fig-
ure 1A). Among the elderly, (neo-)adjuvant chemotherapy or
radiotherapy was hardly used. The percentage of patients
receiving thoracic radiotherapy alone has slightly decreased
since 1989 from 11 to 9% but remained more than 30% for
those aged 75 years or older.
Since 1989, the percentage of patients with stage II
disease undergoing resection decreased from 89 to 79%
among those younger than 60 years (p  0.001), from 71 to
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62% among those 60 to 74 years (p  0.001) and remained
about 25% among patients aged 75 years or older. Since
1999, the proportion of patients younger than 75 years re-
ceiving (neo-)adjuvant chemotherapy increased significantly,
but this treatment was hardly used among the elderly patients
(Figure 1B). The proportion receiving (neo-)adjuvant radio-
therapy has only decreased among those younger than 75
years (Figure 1B). The percentage of patients receiving tho-
racic radiotherapy alone has increased since 1989 from 17 to
21% (p  0.01) and remained more than 40% for those aged
75 years or older.
Stages III and IV
The introduction of chemoradiation for stage III was
the most prominent change among young patients since 1997,
followed by a similar change in the elderly since 2000. In
2004–2009, chemoradiation for stage IIIA was applied in
56% of patients younger than 60 years and in 45% of patients
aged 60 to 74 years, compared with 12 and 5%, respectively,
in the period 1994–1998 (Figure 1C). Chemoradiation for
stage IIIB was applied in 41% of patients younger than 60
years in 2004–2009 and in 31% of patients aged 60 to 74
years, compared with 10 and 4%, respectively, in the period
1994–1998. Among patients aged 75 years or older, the
proportion receiving chemoradiation in stage IIIA was 18 and
10% in stage IIIB in 2004–2009. Among those younger than
75 years, more patients received only chemotherapy than
only radiotherapy and vice versa for those aged 75 years or
older (results not shown). The proportion receiving chemo-
therapy alone increased significantly from 2 to 18% in stage
IIIA and from 4 to 26% in stage IIIB (p  0.001 in all age
groups), whereas the proportion receiving only (palliative)
radiotherapy declined significantly over time from 64 to 18%
in stage IIIA and from 60 to 15% in stage IIIB (p  0.001 in
all age groups).
Few stage III patients were eligible for surgery,
whether or not combined with chemoradiation. The propor-
tion of patients younger than 75 years undergoing surgery
decreased from 25 to 15% in stage IIIA (p  0.001 in all age
groups) and increased from 8 to 10% in stage IIIB (p 0.003
in all age groups). For patients aged 75 years or older, this
proportion decreased from 10 to 5% in stage IIIA (p 0.001)
and did not change in stage IIIB (3%, p  0.45).
Since the mid-1990s, the proportion of stage IV pa-
tients receiving chemotherapy increased significantly among
those younger than 60 years from 14% in 1989–1993 to 63%
in 2004–2009 and among those aged 60 to 74 years from 5 to
47% (Figure 1D). Among patients aged 75 years or older, this
proportion increased significantly from 5 to 21% since 2000.
Trends in Survival
Five-year relative survival for all patients improved
significantly since 2005, from 14.8% in 1989–1993 to 16.1%
in 2004–2009 (p  0.003) and was 17.4% in the year 2009.
Five-year relative survival for females improved significantly
from 14% in 1989–1993 to 18% in 2004–2009 (p  0.001),
whereas 5-year relative survival for males remained stable at
15%. Improvements in survival were observed among all age
groups (75 years from 16 to 18%, p  0.01, and 75 years
from 9 to 11%, p  0.001) and for patients with squamous
TABLE 1. Clinical and Tumor Characteristics of Patients with Non-small Cell Lung Cancer by Period of Diagnosis
Number of Patients per Period of Diagnosis (%)
pa1989–1993 1994–1998 1999–2003 2004–2009
Total 32,514 33,676 34,102 47,468
Gender 0.001
Male 27,487 (85) 26,600 (79) 24,805 (73) 31,192 (66)
Female 5027 (15) 7076 (21) 9297 (27) 16,276 (34)
Age (years) 0.001
60 7064 (22) 7733 (23) 8668 (25) 11,988 (26)
60–74 17,521 (54) 17,806 (53) 17,002 (50) 23,189 (49)
75 7929 (24) 8137 (24) 8432 (25) 12,291 (26)
Stage (cTNM) 0.001
In situ 4 (0) 4 (0) 2 (0) 1 (0)
I 9150 (28) 9224 (27) 7573 (22) 9675 (20)
II 1103 (3) 857 (3) 1687 (5) 2056 (4)
III 11,490 (35) 12,389 (37) 11,238 (33) 13,999 (30)
IV 7930 (24) 8927 (27) 12,106 (36) 20,803 (44)
Unknown 2837 (9) 2275 (7) 1496 (4) 934 (2)
Histology 0.001
Squamous 17,014 (52) 14,959 (44) 12,556 (37) 13,947 (29)
Adenocarcinoma 8185 (25) 9941 (30) 10,815 (32) 17,434 (36)
Large cell 6686 (21) 8296 (25) 10,290 (30) 15,471 (34)
Other 629 (2) 480 (1) 441 (1) 616 (1)
a p: period 2004–2009 compared with 1989–1993 tested by the 2 test.
cTNM, tumor, node, metastasis.
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cell carcinomas (from 17 to 20%, p  0.001) and nonsqua-
mous cell carcinomas (from 11 to 14%, p  0.001).
Statistically significant improvements in relative sur-
vival over time were seen in stages I, III, and IV (Figure 2).
Survival rates according to treatment per stage and age group
are presented in Figure 3. Relative survival was better for
standard of care therapy in all stages and for all age groups.
After adjustment for sex, age, and morphology, the RER of
dying within the first 5 years after being diagnosed with stage
I in 2004–2009 was significantly lower as compared with
1989–1993 (RER  0.62) (Table 2). After additional adjust-
ment for changes in treatment over time, the prognostic effect
for period of diagnosis became slightly smaller but remained
significant (RER 0.69). This was also true for patients with
stage II and IIIA/B disease (RER stage II  0.84, after
adjustment for treatment RER  0.78, and RER stage IIIA/
FIGURE 1. Changes in treatment for NSCLC according to stage and age. A, (Neo-)adjuvant therapy stage I. B, (Neo-)adju-
vant therapy stage II. C, Chemoradiation therapy stage III. D, Chemotherapy stage IV. CT, chemotherapy; RT, radiotherapy.
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B  0.72, after adjustment for treatment RER  0.88). For
patients with stage IV NSCLC, the RER of dying within the
first year after diagnosis in 2004–2009 was also significantly
lower as compared with 1989–1993 (RER  0.69), but this
effect disappeared after adjusting for changes in treatment
over time (RER  1.06).
DISCUSSION
This study showed that the proportion of NSCLC pa-
tients receiving the standard treatment according to the Dutch
guidelines of 2004 increased significantly over time com-
pared with the period 1989–2004. Nevertheless, a substantial
part of the patients did not receive this standard treatment,
especially those aged 75 years or older. Five-year relative
survival increased slightly since 2004/2005 for the whole
group, especially in females, younger patients, and within
each stage group, which could only partly be explained by
survival benefits due to treatment.
In this study using nationwide population-based data of
NSCLC patients, more female patients and more patients
with advanced disease and nonsquamous cell carcinomas
were diagnosed over time, as was observed elsewhere.1–4 The
proportion of patients with unknown stage decreased, illus-
trating improvements in staging in recent years.
Trends in Treatment
Surgery is the mainstay of curative therapy and offers
the best chance for survival.22 In accordance with other studies
and conform (inter)national guidelines (www.ikcnet.nl),23 we
found in stage I that almost all patients younger than 60 years
underwent surgery. This proportion increased over time for
all age groups. (Neo-)adjuvant chemotherapy in stage I is not
recommended except for clinical trials,23 and in our study
only a minority received additional chemotherapy. Although
in stage II disease surgery should also be the cornerstone of
treatment, only 80% of the patients younger than 60 years
underwent surgery and this proportion decreased over time.
Resection of stage II tumors is often complicated by the size
of the tumors or hilar lymph node metastases, combined with
comorbidity: around 50% of these patients have chronic
obstructive pulmonary disease.24–27 Another explanation for
the decreased resection rates might be stage migration from
stage IIIA to IIB patients, including T3 tumors, after imple-
mentation of the 5th edition of the UICC TNM Classification
in 1999. Resection rates may improve by centralizing surgical
treatment and by implementing multidisciplinary meetings in
which treatment strategies can be discussed.28,29 In the Neth-
erlands, relatively and significantly more patients received
(neo-)adjuvant chemotherapy since 2004, in accordance with
international observations.15,30–32
In stage III disease, combined chemo- and radiotherapy
became standard of care since the early 1990s, replacing the
use of radiotherapy alone.33,16,34 Earlier application of radio-
therapy in concurrent schedules together with more accurate
radiotherapy techniques have been achieved.16 Indeed, the
proportion receiving chemoradiation among stage III patients
increased considerably, although its use was still low
(50%). Chemoradiation was used more frequently for stage
IIIA than stage IIIB patients. This is probably due to the
diversity of TNM subsets in stage IIIB including those in
which radical radiotherapy cannot be applied, such as pleu-
ritis carcinomatosa (T4 in this TNM staging and nowadays
M1a in the new TNM staging of 2009) or large therapy fields
including supraclavicular nodal disease (N3) and decreased
pulmonary function.19,35 In advanced lung cancer (stage IV),
palliative treatment aims to improve or maintain quality of
life. Since the 1990s, several studies have shown that platin-
based palliative chemotherapy also prolongs survival and is
indicated for patients with good performance status and
recommended in current guidelines.36,37 In our study, more
FIGURE 2. Trends in relative survival of non-small cell lung
cancer according to stage and period of diagnosis.
FIGURE 3. Relative survival of non-small cell lung cancer
patients according to standard of care therapy per stage in
2004–2009.
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than 50% of patients younger than 60 years received chemo-
therapy with remarkable increases since the late nineties.
In line with other studies, about 25% of the NSCLC
population was aged 75 years or older.13 In our study, elderly
received less intensive treatment in every stage compared
with younger patients, probably reflecting the higher preva-
lence of multiple comorbid conditions, frailty, and higher
operative risks.26,38,27 Older lung cancer patients have ap-
proximately twice as many comorbidities compared with the
general population, chronic obstructive pulmonary disease
occurring most frequently. Video-assisted thoracic surgery-
lobectomy, a new surgical technique, offers possibilities for
the elderly but was hardly applied in our study period because
only few centers were offering such treatments.39 The use of
(neo-)adjuvant chemotherapy in stage II was hardly imple-
mented in elderly in the Netherlands as was also shown in a
French study.31 The proportion of older patients receiving
only radiotherapy did not change over time, being around
30% in stage I and almost 50% in stage II, while being almost
absent in younger patients. Similar proportions were ob-
served in a Canadian population-based study.40 Since 2002,
there is an increased availability of stereotactic body radio-
therapy, a new approach that delivers high radiotherapy doses
in short treatment times. Because short-term treatment-re-
lated toxicity is low, stereotactic body radiotherapy is appeal-
ing for patients with comorbidity, bad performance status,
and elderly.41,42
The proportion receiving chemoradiation among older
stage III patients increased considerably, although its use was
still low (20%). Besides age, comorbidity and the diversity
of TNM subsets in this stage are main obstacles for applying
chemoradiation. In stage III clinical studies, less than 20% of
patients aged 70 years or older received chemoradiation.34
Therefore, it is not known whether the results of these studies
can be extrapolated to elderly lung cancer patients.34 In our
study, up to 40% of older stage III patients did not receive
any therapy. In line with observations from other studies,
elderly stage IV lung cancer patients received less chemo-
therapy than younger patients, although this proportion has
started to increase (up to 24% in our study in 2009).43–45
Trends in Survival
In our study, 5-year relative survival of all patients with
NSCLC together improved slightly since 2004/2005 to
17.4%. Better compliance to treatment strategies with clinical
service standards such as guidelines could have contributed to
better survival at population level.46,47 With improved stag-
ing, patients with previous early stage disease will be up-
staged (stage migration) which results in improved survival
for all stage groups (Will Rogers phenomenon). The routine
use of fluorodeoxyglucose-positron emission tomography and
integrated positron emission tomography-computed tomogra-
phy in the diagnostic work-up of patients with early stage
lung cancer since 2000 led to a stage shift toward higher
stages.8,9 Minimally invasive techniques such as esophageal
or endobronchial endoscopic ultrasound enhanced the accu-
racy of mediastinal staging and may also have attributed to a
stage shift.11 However, in line with other studies, we observed
a survival improvement for females and younger patients
including all stages which would not be the case if only stage
migration plays a role.27,48,49 We investigated whether the
effect of time period on survival could be explained by
changes in treatment by adding treatment variables in the
multivariable analyses. Five-year relative survival of patients
with stage I and II improved over time. This effect became
slightly smaller but remained significant after adjusting for
TABLE 2. Multivariable Relative Survival Analysis of NSCLC in the Netherlands, 1989–2009
Period of Diagnosis
Multivariable Model 1
(Adjusted for Sex, Age,
and Histology)
Multivariable Model 2
(Adjusted for Sex, Age,
Histology, and Treatment)
RER 95% CI RER 95% CI
Stage I (5-yr survival) 1989–1993 Ref. Ref.
1994–1998 0.96 0.92–1.01 1.00 0.96–1.05
1999–2003 0.82 0.78–0.86 0.88 0.84–0.93
2004–2009 0.62 0.59–0.65 0.69 0.66–0.73
Stage II (5-yr survival) 1989–1993 Ref. Ref.
1994–1998 0.94 0.86–1.02 0.99 0.91–1.07
1999–2003 1.06 0.98–1.14 1.01 0.94–1.09
2004–2009 0.84 0.77–0.91 0.78 0.72–0.84
Stage III (3-yr survival) 1989–1993 Ref. Ref.
1994–1998 1.00 0.97–1.03 1.01 0.99–1.04
1999–2003 0.89 0.86–0.91 0.98 0.95–1.01
2004–2009 0.72 0.70–0.74 0.88 0.85–0.90
Stage IV (1-yr survival) 1989–1993 Ref. Ref.
1994–1998 0.98 0.94–1.01 1.05 1.02–1.09
1999–2003 0.79 0.76–0.81 1.02 0.99–1.05
2004–2009 0.69 0.67–0.71 1.06 1.02–1.09
RER, relative excess risk of dying; 95% CI, 95% confidence interval.
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changes in treatment in stage I. This indicates that only part
of this improvement can be explained by the higher resection
rates. Improvements in preoperative patient selection includ-
ing multidisciplinary decision making, better staging, better
anesthetic techniques, and peri- and postoperative care may
have contributed to improved survival as well.28,50 Several
nonrandomized studies have shown improvement in overall
survival by stereotactic body radiotherapy in stage I and this
potential effect has to be awaited in our population-based
data.41,42 Adjusting for changes in treatment in stage II did
not affect 5-year relative survival corresponding to the ob-
served lower resection rates. The increased application of
(neo-)adjuvant chemotherapy in this stage is expected to
improve survival as was shown in several clinical studies and
meta-analysis, but the effects on 5-year survival could not yet
be detected.51
In the Netherlands, 3-year relative survival for stage
IIIA and IIIB disease increased significantly over time,
largely because of upstaging from stage IIIA to IIB patients
after implementation of the 5th edition of the UICC TNM
Classification and also due to the use of chemoradiation, as
shown in multivariable analyses. Recent studies indicate that
overall survival might be further improved by administrating
chemoradiation concurrently instead of sequentially but at the
cost of more complications.52,34 Also patients with significant
comorbidity or older age but with a good performance status
can achieve similar survival rates as younger patients.33,53
Other studies showed that in a selected group of downstaged
stage III patients including patients with N0 status after
chemoradiation, lobectomy may further improve overall sur-
vival.54 In our study, 1-year relative survival for stage IV
patients younger than 60 years doubled to 21% since 1989.
These significant improvements over time disappeared after
adjusting for the use of chemotherapy, implying that the
increased use of chemotherapy could at least partly explain
the improvements in survival. Previous platin-based studies
showed improvement of survival, and in the last years,
applying newer chemotherapy regimens according to either
histological subtype or targeted therapy aimed at somatic
mutations in receptors or signal proteins (e.g., endothelial
growth factor receptor) resulted in improved 1-year survival
especially in adenocarcinomas.37,55,56 Further improvement in
survival due to personalized treatment is expected in the near
future. In our study, survival of older unselected stage IV
patients was poorer compared with younger patients. Among
selected patient groups, no survival differences were shown
for fit elderly compared with younger patients, and therefore
in the current guidelines, chemotherapy is also recommended
for the fit elderly.36,45,57
The increased incidence of nonsquamous cell carcino-
mas due to changes in the World Health Organization histo-
logical typing of NSCLC could also have contributed to
improved survival. Among others, the current “not otherwise
specified” category has been long time mixed in the large cell
subgroup. Also, the incidence of NSCLC in never smokers
is increasing, especially in women and nonsquamous cell
carcinomas. Possible causes are genetic, biologic, and
hormonal factors and perhaps some factors related to the
environment and lifestyle.58,7 Furthermore, the better treat-
ment strategies in adenocarcinomas might have resulted in
improved survival.
Our results are based on all NSCLC patients diagnosed
in the past 20 years in the Netherlands but nevertheless have
the following limitations: detailed information about diagnos-
tic procedures, surgical techniques, thoracic radiotherapy
dose, choice of chemotherapy and number of cycles, and
comorbidity are not routinely recorded by the cancer regis-
tries. Therefore, the effect of newer treatment strategies can
only be estimated.
In conclusion, on a population-based level, adoption of
standard of care treatment according to the current guidelines
increased significantly over time to about 60% of the patients
younger than 75 years. Although increased, this proportion
was considerably less for those aged 75 years or older (about
20%). Improvements in application of standard therapy were
most prominent since 2000 and the Dutch treatment guideline
for NSCLC is started to get implemented. Over a 20-year
period, small improvements in survival have been made for
all stages despite improvement in staging and primary treat-
ment. Since 2004/2005, 5-year relative survival increased
slightly for the whole group, especially in females, younger
patients, and within each stage group. Better adherence to
therapy whenever possible may further improve survival
besides personalized treatment strategies.
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